Melanoma: What do all the mutations mean?
暂无分享,去创建一个
[1] Yu-Ying He,et al. Mechanisms and prevention of UV‐induced melanoma , 2018, Photodermatology, photoimmunology & photomedicine.
[2] T. Chan,et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.
[3] A. Hauschild,et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.
[4] D. Carbone,et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer , 2017 .
[5] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[6] J. Utikal,et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.
[7] Charles H. Yoon,et al. An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.
[8] Donavan T. Cheng,et al. PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. , 2017, JCO precision oncology.
[9] M. Socinski,et al. First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[10] M. Bosenberg,et al. Melanocytic nevi and melanoma: unraveling a complex relationship , 2017, Oncogene.
[11] B. Bastian,et al. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. , 2017, Cancer cell.
[12] Catherine A. Shang,et al. Whole-genome landscapes of major melanoma subtypes , 2017, Nature.
[13] Levi Garraway,et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.
[14] D. Schadendorf,et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. , 2017, The Lancet. Oncology.
[15] L. Saal,et al. NF1‐mutated melanoma tumors harbor distinct clinical and biological characteristics , 2017, Molecular oncology.
[16] D. Schadendorf,et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. , 2016, The Lancet. Oncology.
[17] J. Luke,et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma , 2016, Proceedings of the National Academy of Sciences.
[18] P. A. Futreal,et al. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set , 2016, BMC Medicine.
[19] K. Flaherty,et al. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Matthew Wongchenko,et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. , 2016, The Lancet. Oncology.
[21] J. Sosman,et al. Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum , 2016, Pigment cell & melanoma research.
[22] R. Bourgon,et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.
[23] D. Felsher,et al. MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.
[24] J. Sosman,et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.
[25] J. McQuade,et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.
[26] C. Berking,et al. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. , 2015, European journal of cancer.
[27] R. Dummer,et al. The Genetic Evolution of Melanoma from Precursor Lesions. , 2015, The New England journal of medicine.
[28] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[29] R. Schreiber,et al. The odds of immunotherapy success , 2015, Science.
[30] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[31] A. Aplin,et al. RAC1 P29S regulates PD‐L1 expression in melanoma , 2015, Pigment cell & melanoma research.
[32] I. Yeh,et al. Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion , 2015, Pigment cell & melanoma research.
[33] S. Ariyan,et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas , 2015, Nature Genetics.
[34] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Steven J. M. Jones,et al. Genomic Classification of Cutaneous Melanoma , 2015, Cell.
[36] M. Stratton,et al. High burden and pervasive positive selection of somatic mutations in normal human skin , 2015, Science.
[37] D. Schadendorf,et al. BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. , 2015 .
[38] T. Gajewski,et al. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.
[39] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[40] A. Iafrate,et al. Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies , 2015, Cancer Immunology Research.
[41] J. Larkin,et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. , 2015, Cancer cell.
[42] N. Bardeesy,et al. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. , 2015, Cancer cell.
[43] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[44] Richard F. Kefford,et al. Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients , 2014, Clinical Cancer Research.
[45] K. Dutton-Regester,et al. BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib , 2014, Pigment cell & melanoma research.
[46] Gordon B Mills,et al. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. , 2014, Cancer research.
[47] D. Schadendorf,et al. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. , 2014, Journal of the National Cancer Institute.
[48] S. Puig,et al. Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions , 2014, International journal of cancer.
[49] S. Fox,et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines , 2014, Pigment cell & melanoma research.
[50] G. Linette,et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. , 2014, JAMA.
[51] B. Taylor,et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. , 2014, Cancer research.
[52] Michael A. Davies,et al. Pathways and therapeutic targets in melanoma , 2014, Oncotarget.
[53] Iwei Yeh,et al. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy , 2013, Pigment cell & melanoma research.
[54] A. D. Van den Abbeele,et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[56] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[57] A. Iafrate,et al. NRAS mutation: A potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM). , 2013 .
[58] S. O'toole,et al. BRAF inhibitor activity in V600R metastatic melanoma. , 2013, European journal of cancer.
[59] K. Flaherty,et al. Elucidating distinct roles for NF1 in melanomagenesis. , 2013, Cancer discovery.
[60] M. Berger,et al. Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma , 2013, Clinical Cancer Research.
[61] S. Kweon,et al. BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas. , 2013, The Journal of investigative dermatology.
[62] Junfeng Xia,et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. , 2012, Cancer discovery.
[63] A. Rademaker,et al. The role of 8q24 copy number gains and c-MYC expression in amelanotic cutaneous melanoma , 2012, Modern Pathology.
[64] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[65] A. Sivachenko,et al. A Landscape of Driver Mutations in Melanoma , 2012, Cell.
[66] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[67] Matthew J. Davis,et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.
[68] Dirk Schadendorf,et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .
[69] Lauren E Haydu,et al. Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma , 2012, Clinical Cancer Research.
[70] William Pao,et al. Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials , 2012, PloS one.
[71] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[72] K. Flaherty,et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] G. Mann,et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] J. Malvehy,et al. Genome-wide association study identifies three loci associated with melanoma risk , 2009, Nature Genetics.
[75] R. DePinho,et al. BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.
[76] D. Pinkel,et al. Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] S. Puig,et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents , 2006, Journal of Medical Genetics.
[78] Stephen B Gruber,et al. BRAF and NRAS mutations in melanoma and melanocytic nevi , 2006, Melanoma research.
[79] J. Fridlyand,et al. Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.
[80] Takayuki Kosaka,et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] D. Tuveson,et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. , 2005, Cancer research.
[82] Rossella Bertulli,et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.
[83] F. Haluska,et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. , 2004, The Journal of investigative dermatology.
[84] Ajay N. Jain,et al. Determinants of BRAF mutations in primary melanomas. , 2003, Journal of the National Cancer Institute.
[85] Rui Qiao,et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. , 2003, Cancer research.
[86] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[87] R. Fisher,et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] P S Harper,et al. Molecular genetics of neurofibromatosis type 1 (NF1). , 1996, Journal of medical genetics.
[89] W. Clark,et al. Germline p16 mutations in familial melanoma , 1994, Nature Genetics.
[90] S. Rosenberg,et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.
[91] D. Mccormick. Sequence the Human Genome , 1986, Bio/Technology.
[92] Alexander V Penson,et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. , 2018, Cancer cell.
[93] Antoni Ribas,et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.
[94] Jeffrey W. Clark,et al. Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer , 2014 .
[95] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .
[96] Jochen K. Lennerz,et al. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair / fair skin background , 2012 .
[97] P. Meltzer,et al. High frequency of BRAF mutations in nevi , 2003, Nature Genetics.
[98] International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome , 2001, Nature.